Clinical Trial

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

Study acronym: CDPP
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).
Trial Details
NCT Number NCT05105321
Lead Sponsor Tang Yida
Collaborators: Chinese Society of Cardiology
Conditions Metabolic Syndrome
Enrollment 5,200 participants
Start Date 2021-12
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2021-11-03